Pathogen Inactivation for Blood Products, Protein Therapeutics and Vaccines – CFI
For the physical inactivation of enveloped and non-enveloped viruses with no residual contamination and negligible denaturation of proteins and enzymes
The worldwide AIDS epidemic, the periodic emergence of Ebola and SARS, and the recent outbreaks of potentially pandemic strains of influenza such as H5N1 have highlighted a persistent concern in the health-care community – the need for effective pathogen inactivation and removal techniques for human blood plasma and plasma-derived products.
A number of approaches have been employed for the inactivation or removal of viruses in human plasma and therapeutic proteins derived from human plasma, including: heating or pasteurization; solvent-detergent technique; Ultra Violet (UV) irradiation; and chemical inactivation. Current approaches are not always effective against a wide spectrum of human and animal viruses, are sometimes encumbered by process-specific deficiencies, and often result in denaturation of the biologics that they are designed to protect.
The CFI Solution
CFI works by first permeating and inflating the pathogen particles with a selected supercritical, critical or near-critical fluid with or without polar cosolvents [SuperFluids™ or SFS]. The ultra-low interfacial tension of SuperFluids™ allows facile penetration into microporous structures. As such, SuperFluids™ can readily penetrate and inflate viral particles.
The overfilled particles are then decompressed. The dense-phase fluid rapidly changes into a gaseous state, rupturing the pathogen particles at their weakest points – very much like the embolic disruption of the ear drums of a scuba diver who surfaces too rapidly – and becomes inactive.
The now gaseous SFS leaves the protein-rich substrate with no toxic residuals to be removed.
CFI, especially when used with conventional virus inactivation or removal methods such as Solvent-Detergent or Nanofiltration, will help ensure a blood supply that is safe from emerging and unknown pathogens and bioterrorism threats.
In addition to human plasma and human plasma proteins such as fibrinogen, the developed technology will also be applicable to recombinant therapeutics, monoclonal antibodies, transgenics and vaccines.
We will work with strategic corporate partners and medical institutions to implement a pathogen inactivation technology that is purely physical and effective without product denaturation for your virus clearance and vaccine applications.